<DOC>
	<DOCNO>NCT00646399</DOCNO>
	<brief_summary>Evaluate safety , PK efficacy compare Pagibaximab Injection placebo prevent staphylococcal sepsis low birth weight infant . 1550 infant enrol prior 48 hour life randomize 1:1 receive active drug placebo study day 0 , 1 , 2 , 9 , 16 , 23 .</brief_summary>
	<brief_title>Safety Efficacy Pagibaximab Injection Very Low Birth Weight Neonates Prevention Staphylococcal Sepsis</brief_title>
	<detailed_description>Phase 2b/3 , randomize , double-blind , multicenter , placebo-controlled study evaluate safety , efficacy pharmacokinetics ( PK ) pagibaximab ( 100 mg/kg/dose ) comparison placebo prevention staphylococcal sepsis VLBW infant ( 600 -1200 gram ) . Subjects monitor treatment related adverse event tolerability infusion study drug . Neonatal sepsis assess presence clinical sign symptoms one blood culture positive S. aureus two blood culture positive Coagulase Negative Staphylococci ( CoNS ) . The study period 35 day first dose , death , discharge , transfer , whichever occur first .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Birth Weight</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<criteria>1 . Inpatient Neonatal Intensive Care Unit ( NICU ) 2 . Informed consent obtain legally authorize representative 3 . Less 48 hour old time first infusion 4 . Birth weight 600 gram 1200 gram 5 . Estimated gestation age â‰¤33 week For multiple gestation , twin may enrol meet entry criterion . They assign treatment group . 1 . Infants history hypersensitivity severe vasomotor reaction antibody preparation . 2 . Infants proven staphylococcal infection prior randomization . 3 . Infants concomitant infection medical condition , whose participation , opinion Investigator and/or medical advisor , may create unacceptable additional risk . 4 . Immunodeficiency due prematurity . 5 . Currently receive , recently receive , plan receive investigational agent could interfere conduct result study . 6 . Severe congenital chromosomal anomaly would limit life expectancy require corrective measure period study 7 . Uncontrolled seizure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>48 Hours</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Staphylococcal</keyword>
	<keyword>Coagulase Negative Staphylococcus</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Very Low Birth Weight Infants</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>